Patent intelligence · US
US 12268720
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
Patent details — US 12268720
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 8, 2025
- Expiration
- Apr 3, 2045
- Applicant
- Armata Pharmaceuticals, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K35/76, A61K35/768, A61K39/12
Quick answer
US 12268720 (Bacteriophage for treatment and prevention of E. coli and B. fragilis infections) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted Apr 8, 2025. Expires Apr 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Armata Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K35/76, A61K35/768, A61K39/12, A61K45/06
More from Armata Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12239677
Therapeutic bacteriophage compositions for treating Staphylococcus infection
granted -
US 11654166
Therapeutic bacteriophage compositions for treating Staphylococcus infection
granted -
US 11253557
Therapeutic bacteriophage compositions
granted -
US 10517908
Therapeutic bacteriophage compositions
granted
Frequently asked questions
What is US patent 12268720?
US 12268720 (Bacteriophage for treatment and prevention of E. coli and B. fragilis infections) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted Apr 8, 2025. Expires Apr 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12268720?
Armata Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12268720 expire?
Our index shows an expiration date of Apr 3, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.